STUDY OBJECTIVE: The aim of this study is to evaluate the efficacy of aprepitant as part of the antiemetic regimen for high-dose melphalan conditioning in multiple myeloma patients. DESIGN: This is a prospective, single-arm study. SETTING: The study was conducted at an Academic Medical Facility. SUBJECTS: Twenty-six patients receiving high-dose melphalan with autologous stem cell support were included in this study. INTERVENTION: Eligible patients were >18 years with a diagnosis of MM undergoing high-dose melphalan followed by autologous peripheral blood stem cell transplantation (PBSCT). All patients had serum aminotransferases and total bilirubin less than 2× upper limit of normal. Treatment consisted of aprepitant 125 mg orally on day 1, followed by 80 mg orally 24 and 48 h after the initial dose; ondansetron 16 mg orally day 1; dexamethasone 12 mg orally day 1, and 8 mg orally days 2-4 with breakthrough medications as needed. MEASUREMENTS AND MAIN RESULTS: Patients were evaluated for the frequency of emetic episodes, the need for breakthrough antiemetic medication, and the mean nausea score in 24-h increments beginning 24 h after chemotherapy and continuing until 120 h. Nausea score was determined using a linear analog scale (0-10). Complete response (CR) was defined as no more than one (1) emetic episode during the evaluation period. A total of 26 patients (17 male, 9 female) were enrolled in the study. Of these, 25 (96 %) were complete responders and 24 (92 %) had no documented emetic episodes during the study period. One patient (4 %) had 1 emetic episode and one patient (4 %) had 2 emetic episodes. Some degree of nausea was reported by 23/26 patients, and the mean nausea score for the entire group over the study period was 0.7 (range 0-10). CONCLUSIONS: Addition of aprepitant to standard antiemetics resulted in low rates of delayed nausea/vomiting associated with high-dose melphalan and PBSCT, and has now become standard practice in this patient population at our institution.
STUDY OBJECTIVE: The aim of this study is to evaluate the efficacy of aprepitant as part of the antiemetic regimen for high-dose melphalan conditioning in multiple myelomapatients. DESIGN: This is a prospective, single-arm study. SETTING: The study was conducted at an Academic Medical Facility. SUBJECTS: Twenty-six patients receiving high-dose melphalan with autologous stem cell support were included in this study. INTERVENTION: Eligible patients were >18 years with a diagnosis of MM undergoing high-dose melphalan followed by autologous peripheral blood stem cell transplantation (PBSCT). All patients had serum aminotransferases and total bilirubin less than 2× upper limit of normal. Treatment consisted of aprepitant 125 mg orally on day 1, followed by 80 mg orally 24 and 48 h after the initial dose; ondansetron 16 mg orally day 1; dexamethasone 12 mg orally day 1, and 8 mg orally days 2-4 with breakthrough medications as needed. MEASUREMENTS AND MAIN RESULTS:Patients were evaluated for the frequency of emetic episodes, the need for breakthrough antiemetic medication, and the mean nausea score in 24-h increments beginning 24 h after chemotherapy and continuing until 120 h. Nausea score was determined using a linear analog scale (0-10). Complete response (CR) was defined as no more than one (1) emetic episode during the evaluation period. A total of 26 patients (17 male, 9 female) were enrolled in the study. Of these, 25 (96 %) were complete responders and 24 (92 %) had no documented emetic episodes during the study period. One patient (4 %) had 1 emetic episode and one patient (4 %) had 2 emetic episodes. Some degree of nausea was reported by 23/26 patients, and the mean nausea score for the entire group over the study period was 0.7 (range 0-10). CONCLUSIONS: Addition of aprepitant to standard antiemetics resulted in low rates of delayed nausea/vomiting associated with high-dose melphalan and PBSCT, and has now become standard practice in this patient population at our institution.
Authors: Javier López-Jiménez; Eva Martín-Ballesteros; Anna Sureda; Carla Uralburu; Ignacio Lorenzo; Raquel del Campo; Cristina Fernández; María Calbacho; Daniel García-Belmonte; Gonzalo Fernández Journal: Haematologica Date: 2006-01 Impact factor: 9.941
Authors: Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman Journal: J Clin Oncol Date: 2011-09-26 Impact factor: 44.544
Authors: K K Ballen; A M Hesketh; C Heyes; P S Becker; R V Emmons; K Fogarty; J LaPointe; Q Liu; C C Hsieh; P J Hesketh Journal: Bone Marrow Transplant Date: 2001-12 Impact factor: 5.483
Authors: Paul J Hesketh; Steven M Grunberg; Richard J Gralla; David G Warr; Fausto Roila; Ronald de Wit; Sant P Chawla; Alexandra D Carides; Juliana Ianus; Mary E Elmer; Judith K Evans; Klaus Beck; Scott Reines; Kevin J Horgan Journal: J Clin Oncol Date: 2003-10-14 Impact factor: 44.544
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Patrick J Stiff; Mary P Fox-Geiman; Karen Kiley; Karen Rychlik; Mala Parthasarathy; Donna Fletcher-Gonzalez; Nancy Porter; Aileen Go; Scott E Smith; Tulio E Rodriguez Journal: Biol Blood Marrow Transplant Date: 2012-08-01 Impact factor: 5.742
Authors: Lawrence H Einhorn; Bernardo Rapoport; Rudolph M Navari; Jørn Herrstedt; Mary J Brames Journal: Support Care Cancer Date: 2016-11-04 Impact factor: 3.603